{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:01:44Z","timestamp":1790276504641,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,19]]},"DOI":"10.7759\/cureus.75993","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T04:59:01Z","timestamp":1734584341000},"source":"Crossref","is-referenced-by-count":4,"title":["The Bidirectional Relationship Between Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Cohort Study"],"prefix":"10.7759","author":[{"given":"David M","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumaina","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Cragg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin L","family":"Ch'ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namor W","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thinzar","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments","volume":"18","author":"Targher G","year":"2021","unstructured":"Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021, 18:599-612. 10.1038\/s41575-021-00448-y","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"71","author":"Younossi ZM","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, et al.. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019, 71:793-801. 10.1016\/j.jhep.2019.06.021","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-013-2743-5","article-title":"Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD)","volume":"58","author":"Stepanova M","year":"2013","unstructured":"Stepanova M, Rafiq N, Makhlouf H, et al.. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2013, 58:3017-23. 10.1007\/s10620-013-2743-5","journal-title":"Dig Dis Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals","volume":"70","author":"Mantovani A","year":"2021","unstructured":"Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut. 2021, 70:962-9. 10.1136\/gutjnl-2020-322572","journal-title":"Gut"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis","volume":"41","author":"Mantovani A","year":"2018","unstructured":"Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care. 2018, 41:372-82. 10.2337\/dc17-1902","journal-title":"Diabetes Care"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2010.518623","article-title":"Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity","volume":"43","author":"Musso G","year":"2011","unstructured":"Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011, 43:617-49. 10.3109\/07853890.2010.518623","journal-title":"Ann Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14196","article-title":"A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer?","volume":"22","author":"Vincent RK","year":"2020","unstructured":"Vincent RK, Williams DM, Evans M. A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer?. Diabetes Obes Metab. 2020, 22:2227-40. 10.1111\/dom.14196","journal-title":"Diabetes Obes Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella ME","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al.. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023, 77:1797-835. 10.1097\/HEP.0000000000000323","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD)","volume":"28","author":"Cusi K","year":"2022","unstructured":"Cusi K, Isaacs S, Barb D, et al.. American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022, 28:528-62. 10.1016\/j.eprac.2022.03.010","journal-title":"Endocr Pract"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"European Association for the Study of the Liver (EASL)","year":"2024","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024, 81:492-542. 10.1016\/j.jhep.2024.04.031","journal-title":"J Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal AJ","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, et al.. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010, 362:1675-85. 10.1056\/NEJMoa0907929","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52603-5","article-title":"Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis","volume":"14","author":"Ong Lopez AM","year":"2024","unstructured":"Ong Lopez AM, Pajimna JA. Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis. Sci Rep. 2024, 14:2122. 10.1038\/s41598-024-52603-5","journal-title":"Sci Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba R","year":"2023","unstructured":"Loomba R, Abdelmalek MF, Armstrong MJ, et al.. Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023, 8:511-22. 10.1016\/S2468-1253(23)00068-7","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome PN","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, et al.. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021, 384:1113-24. 10.1056\/NEJMoa2028395","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba R","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, et al.. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024, 391:299-310. 10.1056\/NEJMoa2401943","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31608","article-title":"Hepatic fibrosis associates with multiple cardiometabolic disease risk factors: the Framingham Heart Study","volume":"73","author":"Long MT","year":"2021","unstructured":"Long MT, Zhang X, Xu H, et al.. Hepatic fibrosis associates with multiple cardiometabolic disease risk factors: the Framingham Heart Study. Hepatology. 2021, 73:548-59. 10.1002\/hep.31608","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v15.i1.89","article-title":"Rising incidence, progression and changing patterns of liver disease in Wales 1999-2019","volume":"15","author":"Pembroke TP","year":"2023","unstructured":"Pembroke TP, John G, Puyk B, et al.. Rising incidence, progression and changing patterns of liver disease in Wales 1999-2019. World J Hepatol. 2023, 15:89-106. 10.4254\/wjh.v15.i1.89","journal-title":"World J Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions","volume":"94","author":"Brunt EM","year":"1999","unstructured":"Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999, 94:2467-74. 10.1111\/j.1572-0241.1999.01377.x","journal-title":"Am J Gastroenterol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner DE","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, et al.. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005, 41:1313-21. 10.1002\/hep.20701","journal-title":"Hepatology"},{"key":"ref20","unstructured":"Diabetes in Wales. (2023). Accessed. 12\/12\/2024: https:\/\/www.diabetes.org.uk\/support-for-you\/diabetes-uk-in-your-area\/wales\/diabetes-in-wales."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1853","article-title":"Combined influence of insulin resistance, overweight\/obesity, and fatty liver as risk factors for type 2 diabetes","volume":"35","author":"Sung KC","year":"2012","unstructured":"Sung KC, Jeong WS, Wild SH, Byrne CD. Combined influence of insulin resistance, overweight\/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care. 2012, 35:717-22. 10.2337\/dc11-1853","journal-title":"Diabetes Care"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options","volume":"1","author":"Gastaldelli A","year":"2019","unstructured":"Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep. 2019, 1:312-28. 10.1016\/j.jhepr.2019.07.002","journal-title":"JHEP Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2016.1971","article-title":"Prevalence of prediabetes and type 2 diabetes in children with nonalcoholic fatty liver disease","volume":"170","author":"Newton KP","year":"2016","unstructured":"Newton KP, Hou J, Crimmins NA, et al.. Prevalence of prediabetes and type 2 diabetes in children with nonalcoholic fatty liver disease. JAMA Pediatr. 2016, 170:e161971. 10.1001\/jamapediatrics.2016.1971","journal-title":"JAMA Pediatr"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-20-787","article-title":"Accuracy of non-invasive liver stiffness measurement and steatosis quantification in patients with severe and morbid obesity","volume":"10","author":"Eilenberg M","year":"2021","unstructured":"Eilenberg M, Munda P, Stift J, Langer FB, Prager G, Trauner M, Staufer K. Accuracy of non-invasive liver stiffness measurement and steatosis quantification in patients with severe and morbid obesity. Hepatobiliary Surg Nutr. 2021, 10:610-22. 10.21037\/hbsn-20-787","journal-title":"Hepatobiliary Surg Nutr"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14116","article-title":"Prescription of statins in suspected non-alcoholic fatty liver disease and high cardiovascular risk, a population-based study","volume":"39","author":"van den Berg EH","year":"2019","unstructured":"van den Berg EH, Wolters AA, Dullaart RP, Moshage H, Zurakowski D, de Meijer VE, Blokzijl H. Prescription of statins in suspected non-alcoholic fatty liver disease and high cardiovascular risk, a population-based study. Liver Int. 2019, 39:1343-54. 10.1111\/liv.14116","journal-title":"Liver Int"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104392","article-title":"Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study","volume":"87","author":"Ayada I","year":"2023","unstructured":"Ayada I, van Kleef LA, Zhang H, et al.. Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study. EBioMedicine. 2023, 87:104392. 10.1016\/j.ebiom.2022.104392","journal-title":"EBioMedicine"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani A","year":"2021","unstructured":"Mantovani A, Csermely A, Petracca G, et al.. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021, 6:903-13. 10.1016\/S2468-1253(21)00308-3","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324191","article-title":"Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies","volume":"71","author":"Mantovani A","year":"2022","unstructured":"Mantovani A, Petracca G, Beatrice G, Csermely A, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut. 2022, 71:778-88. 10.1136\/gutjnl-2021-324191","journal-title":"Gut"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0471-8","article-title":"SGLT2 inhibitors in type 2 diabetes management: key evidence and implications for clinical practice","volume":"9","author":"Wilding J","year":"2018","unstructured":"Wilding J, Fernando K, Milne N, et al.. SGLT2 inhibitors in type 2 diabetes management: key evidence and implications for clinical practice. Diabetes Ther. 2018, 9:1757-73. 10.1007\/s13300-018-0471-8","journal-title":"Diabetes Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0278685","article-title":"Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: a multivariate meta-analysis","volume":"18","author":"Yeh TL","year":"2023","unstructured":"Yeh TL, Tsai MC, Tsai WH, Tu YK, Chien KL. Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: a multivariate meta-analysis. PLoS One. 2023, 18:e0278685. 10.1371\/journal.pone.0278685","journal-title":"PLoS One"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/322803-the-bidirectional-relationship-between-type-2-diabetes-and-metabolic-dysfunction-associated-steatotic-liver-disease-a-retrospective-cohort-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T04:59:06Z","timestamp":1734584346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/322803-the-bidirectional-relationship-between-type-2-diabetes-and-metabolic-dysfunction-associated-steatotic-liver-disease-a-retrospective-cohort-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.75993","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,19]]}}}